Mogamulizumab, CAS 1159266-37-1

Product Description: Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3].

Applications: COVID-19-anti-virus

Formula: N/A

References: [1]Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4./[2]Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. /[3]Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211(2):238-48. /[4]Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7(7):1175-1187.

CAS Number: 1159266-37-1

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer; Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: CCR

• Artikelnummer: MEXHY-P99253-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99253-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK